ArticlePapillomavirus research (Amsterdam, Netherlands)2020
IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equity".
Article in Papillomavirus research (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Immunopersistence of one or two doses of an Escherichia coli produced bivalent HPV vaccine.NPJ vaccines · 2025Article
- Barriers and strategies to enhance HPV vaccine uptake in adolescents living with HIV and their guardians in Lilongwe, Malawi.Scientific reports · 2025Article
- Acceptance of human papillomavirus vaccine among boys in Asia: A narrative review.Human vaccines & immunotherapeutics · 2024Review
- Accelerating HPV vaccination in Africa for health equity.Global health research and policy · 2024Article
- Review
- Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis.British journal of cancer · 2024Article
- Inequities in human papillomavirus vaccination among children aged 9-14 years old under constrained vaccine supply in China.International journal for equity in health · 2024Article
- The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.Vaccine · 2024Review
- Human papillomavirus (HPV) vaccination program in Sri Lanka: Ongoing costs and operational context of a routinized program.Vaccine: X · 2024Article
- Article
- Review
- Article
- HPV vaccine narratives on Twitter during the COVID-19 pandemic: a social network, thematic, and sentiment analysis.BMC public health · 2023Article
- Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study.Journal of the National Cancer Institute · 2023Article
- Strategies to eliminate cervical cancer in China.Frontiers in oncology · 2023Review
- Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective.Frontiers in immunology · 2023Review
- Cervical cancer prevention program in Mexico disrupted due to COVID-19 pandemic: Challenges and opportunities.Frontiers in oncology · 2023Article
- Human Papillomavirus Vaccination in South Africa: Programmatic Challenges and Opportunities for Integration With Other Adolescent Health Services?Frontiers in public health · 2022Review
- Human Papillomavirus Vaccination After COVID-19.JNCI cancer spectrum · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.